Celltrion, Inc. (KRX:068270)
167,200
-2,800 (-1.65%)
At close: Jun 10, 2026
Celltrion Revenue
Celltrion had revenue of 1.14T KRW in the quarter ending March 31, 2026, with 36.00% growth. This brings the company's revenue in the last twelve months to 4.47T, up 21.94% year-over-year. In the year 2025, Celltrion had annual revenue of 4.16T with 17.01% growth.
Revenue (ttm)
4.47T
Revenue Growth
+21.94%
P/S Ratio
8.38
Revenue / Employee
1.67B
Employees
2,680
Market Cap
37.41T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.16T | 605.19B | 17.01% |
| Dec 31, 2024 | 3.56T | 1.38T | 63.45% |
| Dec 31, 2023 | 2.18T | -107.54B | -4.71% |
| Dec 31, 2022 | 2.28T | 390.57B | 20.63% |
| Dec 31, 2021 | 1.89T | 44.29B | 2.39% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.81T |
| Samsung Epis Holdings | 1.51T |
| SK Biopharmaceuticals | 790.25B |
| SK bioscience | 665.42B |
| ALTEOGEN | 203.76B |
| LigaChem Biosciences | 125.87B |
| HLB Co., Ltd. | 85.20B |
| Voronoi | 7.51B |
Celltrion News
- 4 weeks ago - Celltrion Acquires Gifrer to Expand EU Operations - GuruFocus
- 5 weeks ago - Celltrion Slides: Q1 2026 - Filings
- 5 weeks ago - Celltrion Q1 Net Income Rises - Nasdaq
- 7 weeks ago - Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW) - Benzinga
- 3 months ago - Celltrion Enters Contract Manufacturing Agreement With Global Pharmaceutical Company - Nasdaq
- 3 months ago - Celltrion Announces Commercial Availability In US Of AVTOZMA SC, Tocilizumab Biosimilar - Nasdaq
- 3 months ago - Celltrion Annual report: Q4 2025 - Filings
- 3 months ago - Celltrion Slides: Q4 2025 - Filings